NEW YORK (GenomeWeb) – Bioinformatics firm Congenica today announced it has received £1 million ($1.6 million) from Cambridge Innovation Capital to scale up its Sapientia platform.
Sapientia is a modular and scalable data analytics tool for annotating and clinically interpreting genomic sequence data.
"Sapientia combines clinical information about the patient, information about their gene mutations, and background information about the disease phenotypes of other patients with those mutations," Matthew Hurles, co-founder of Congenica, said in a statement. "We have worked very closely with clinical geneticists to ensure that Sapientia can present this information in a way that is easy for clinicians to interpret."
The technology improves the diagnosis of rare genetic diseases, the Hinxton, UK-based firm said in a statement, and could provide future insights into the screening and treatment of rare and common diseases.
In May, the firm received £200,000 to further develop the platform.
"We see Congenica's technology as a powerful enabler that can realize the potential for a radically different type of genome analysis service," said Cambridge Innovation Capital's Robert Tansley.